Aurora Spine Corporation, a designer and manufacturer of innovative medical devices for spinal surgery, has announced the enrollment of the first patient in its multicenter study of the DEXA-CTM Cervical Interbody System. The study aims to collect important data about the device's impact on patient outcomes. The DEXA-C system is indicated for anterior cervical interbody fusion procedures and is based on Aurora's patented DEXA™ technology platform, which includes implants of varying densities to match a patient's bone density.
The commencement of patient enrollment signifies that Aurora Spine has received all necessary approvals to launch the study. The initial phase will include 40 single level and 40 multiple level subjects. By utilizing a prospective multi-site model, the study hopes to draw objective conclusions and build confidence in the adoption of the DEXA-C device by clinicians across various specialties.
Trent Northcutt, President, CEO, and co-founder of Aurora Spine expressed excitement about the launch of the study, stating that it will provide important data to the medical industry regarding their DEXA platform technology. Dr. Sebastian K